ライフサイエンスコーパス: distant metastasis

1 sectable (286 locally unresectable, 244 with distant metastasis).

2 e site, and/or second primary or regional or distant metastasis).

3 prostate tumor formation, local invasion and distant metastasis.

4 tumors may be associated with more frequent distant metastasis.

5 early breast cancers experience relapse with distant metastasis.

6 odifications during the natural evolution of distant metastasis.

7 tribute to the initiation and progression of distant metastasis.

8 ients have poor prognosis after formation of distant metastasis.

9 ion with radiation, and decrease the risk of distant metastasis.

10 higher probability of nodal involvement and distant metastasis.

11 5 are upregulated in both primary tumors and distant metastasis.

12 ant metastasis to avoid confounding by other distant metastasis.

13 (PET) scan revealed no evidence of nodal or distant metastasis.

14 ouraged for newly diagnosed patients without distant metastasis.

15 logical intervention specifically to prevent distant metastasis.

16 elate significantly with cancer survival and distant metastasis.

17 entation, (2) lymph node metastasis, and (3) distant metastasis.

18 C and EMT programs in local invasiveness and distant metastasis.

19 re recorded, and all patients were free from distant metastasis.

20 ference standard, reviewed PET/CT images for distant metastasis.

21 which also resulted in widespread local and distant metastasis.

22 rove the long-term survival of patients with distant metastasis.

23 term risk of several cancers and the risk of distant metastasis.

24 s: local disease, cervical nodal spread, and distant metastasis.

25 ents with localized breast tumors developing distant metastasis.

26 subtype, CREB3L1 expression is predictive of distant metastasis.

27 ansformation and cell invasion, resulting in distant metastasis.

28 roup of patients at high risk for developing distant metastasis.

29 icantly higher risk for death and recurrence/distant metastasis.

30 r mapped genes, having high correlation with distant metastasis.

31 ancers nor drive progression to the point of distant metastasis.

32 a nearly 5-fold increased risk of developing distant metastasis.

33 cal radiation therapy, and/or development of distant metastasis.

34 carcinoma to poorly differentiated state and distant metastasis.

35 ted in the aggressive formation of liver and distant metastasis.

36 nomas is an effective molecular indicator of distant metastasis.

37 liac node metastasis, and 44 (9.9%) had more distant metastasis.

38 5% CI, 1.25 to 7.59; P = .015) predicted for distant metastasis.

39 th no such metastasis and patients with more distant metastasis.

40 ks analysis was used to estimate the risk of distant metastasis.

41 nt for tumour cell invasion and promotion of distant metastasis.

42 were used to estimate hazard ratios (HRs) of distant metastasis.

43 10-4) were associated with increased risk of distant metastasis.

44 e and selection operator was used to predict distant metastasis.

45 ast cancer tumor prognosticators and risk of distant metastasis.

46 The primary endpoint was the development of distant metastasis.

47 tumorigenic fitness during the evolution of distant metastasis.

48 tumor extension (P=0.017) were predictive of distant metastasis.

49 read and recurrence resulting from local and distant metastasis.

50 ry site was associated with a lower risk for distant metastasis (0.1 [0.0-0.7]) and improved survival

51 tant disease-free survival (hazard ratio for distant metastasis, 0.62; P=0.02) and the 10-year rate o

52 the placebo group (hazard ratio for death or distant metastasis, 0.76; 95.8% CI, 0.64 to 0.92; P=0.00

53 (19.9% v. 25.9%, respectively; P = .97), or distant metastasis (13.0% v. 9.7%, respectively; P = .08

54 had locoregional recurrence and one (2%) had distant metastasis; 2-year progression-free survival was

55 ocal progression (22.2% v 12.3%; P < .0001), distant metastasis (22.8% v 14.8%; P < .0001), biochemic

56 HR, 0.70; 95% CI, 0.51 to 0.96), and time to distant metastasis (adjusted HR, 0.69; 95% CI, 0.59 to 0

57 ccelerated tumor growth, local invasion, and distant metastasis after withdrawal of treatment with so

58 ation to aspirin reduced risk of cancer with distant metastasis (all cancers, hazard ratio [HR] 0.64,

59 er increase best explains the development of distant metastasis among 10 candidate definitions, after

60 (ILRR) of breast cancer have a high risk of distant metastasis and death from breast cancer.

61 se was significantly associated with reduced distant metastasis and death from causes other than canc

62 ology and anaplasia grading as predictors of distant metastasis and death showed that high-risk histo

63 ith clinical stage, pathologic tumor status, distant metastasis and decreased survival of pancreatic

64 Ten-year cumulative incidence of distant metastasis and DFS were 10.5% and 89.5% for pati

65 including cancers, with higher risks of both distant metastasis and early recurrence.

66 nalysis, tumor size, lymph node involvement, distant metastasis and histologic grade were correlated

67 shed a prometastatic role for cathepsin B in distant metastasis and illustrated the therapeutic benef

68 Reduction in distant metastasis and improvements in cancer outcomes a

69 s a problem-solving role in the detection of distant metastasis and in posttreatment evaluation.

70 that miR-1 expression is further reduced in distant metastasis and is a candidate predictor of disea

71 was 22% (95% CI, 12%-32%); 5-year actuarial distant metastasis and locoregional recurrence were 54%

72 y, cell cycle defects, poor differentiation, distant metastasis and metaplasia.

73 ression levels were independently related to distant metastasis and mortality and, if validated, coul

74 ccess the systemic circulation, resulting in distant metastasis and mortality.

75 gative correlation with lymph node invasion, distant metastasis and patient survival in examinations

76 circulating neutrophils are associated with distant metastasis and poor outcome in a number of epith

77 IF-1 and HIF-2 are associated with increased distant metastasis and poor survival in a variety of tum

78 in levels shown previously to correlate with distant metastasis and poor survival.

79 nificantly correlated with increased risk of distant metastasis and reduced relapse-free and overall

80 es with a high incidence of tumor relapse or distant metastasis and shortened survival time in patien

81 e and is highly prognostic for occurrence of distant metastasis and survival in colon cancer patients

82 The true detection rate of distant metastasis and synchronous cancer was assessed f

83 study was to determine the detection rate of distant metastasis and synchronous cancer, comparing cli

84 A model predicting distant metastasis and/or androgen-independent recurrenc

85 dence of mediastinal lymph node involvement, distant metastasis, and 12-mo mortality.

86 icantly associated with biochemical failure, distant metastasis, and any failure.

87 he cumulative incidence of local recurrence, distant metastasis, and disease-free survival (DFS).

88 dent factors prognostic of local recurrence, distant metastasis, and disease-specific survival (DSS).

89 positive human BC, correlates with increased distant metastasis, and is an independent predictor of p

90 ositive correlation with both lymph node and distant metastasis, and it was inversely correlated with

91 , progression-free survival (PFS), actuarial distant metastasis, and locoregional recurrence.

92 ith a worse prognosis, a higher incidence of distant metastasis, and may be more prone to local recur

93 my, breast cancer-specific survival, time to distant metastasis, and overall survival (OS).

94 drive primary tumor growth, regional spread, distant metastasis, and patient death.

95 ing loss of differentiation, local invasion, distant metastasis, and rapid lethality.

96 ), progression-free survival, local failure, distant metastasis, and selected Common Terminology Crit

97 imilarly poor survival as patients with more distant metastasis, and thus may not benefit from surger

98 l differences such as lymph node metastasis, distant metastasis, and triple-negative behavior of tumo

99 risk of local recurrence, lymphatic spread, distant metastasis, and tumor-related death in patients

100 2 cm) and any N stage, or pT2N0; absence of distant metastasis; and no iodine contamination.

101 f the breast, and even more significantly in distant metastasis arising after failed chemotherapy.

102 yed tumor progression and lower incidence of distant metastasis as compared with TRbeta(PV/PV) mice w

103 related with synchronous liver metastasis or distant metastasis-associated disease relapse.

104 diotherapy (n=78) had a greater incidence of distant metastasis at 10 years than did their untreated

105 Freedom from distant metastasis at 10 years was 97% for no factors, 8

106 evealed that, in addition to the presence of distant metastasis at diagnosis (P = 0.001 and 0.001, re

107 verall survival among those who present with distant metastasis at diagnosis (stage 4).

108 ement and one-third of patients already have distant metastasis at diagnosis.

109 ubtype of lung cancer and has a high risk of distant metastasis at every disease stage.

110 lymph nodes involved as well as presence of distant metastasis at presentation.

111 umab treatment significantly associated with distant metastasis at three years.

112 t differences in time to mastectomy, time to distant metastasis, breast cancer-specific survival, or

113 CC is well known for perineural invasion and distant metastasis, but its underlying molecular mechani

114 CTC) have related properties associated with distant metastasis, but the mechanisms through which CSC

115 Oxidative stress thus limits distant metastasis by melanoma cells in vivo.

116 ASTRO] and Phoenix criteria), local failure, distant metastasis, cause-specific mortality, overall mo

117 /MRI correctly detected 3 (1%) patients with distant metastasis, CHCT/MRI detected 11 (4%) patients,

118 ho had radiotherapy had a lower incidence of distant metastasis compared with those who did not have

119 INTERPRETATION: That aspirin prevents distant metastasis could account for the early reduction

120 %; HR, 0.65; P = .07), respectively; 10-year distant metastasis cumulative incidences were 6% (95% CI

121 ositive results in 1%, and in no patient did distant metastasis develop.

122 ied factors that independently predicted for distant metastasis development.

123 The risks of nodal metastasis and distant metastasis did not differ significantly by PNI c

124 kers was significantly associated with worse distant metastasis disease-free survival (hazard ratio [

125 gnostic factor for recurrence-free survival, distant metastasis disease-free survival, and MSS after

126 egressions were applied to the end points of distant metastasis (DM) and cause-specific mortality (CS

127 Locoregional failure (LRF) and distant metastasis (DM) rates were estimated by using th

128 incidence (CCI) of local recurrence (LR) and distant metastasis (DM) were calculated.

129 non-muscle-invasive local failure (LF), and distant metastasis (DM) were estimated by the cumulative

130 Recurrence-free survival (RFS), distant metastasis (DM), and local recurrence (LR) rates

131 ival (OS), disease-specific mortality (DSM), distant metastasis (DM), disease-free survival (DFS), an

132 urrence (RR), locoregional recurrence (LRR), distant metastasis (DM), or freedom from any failure (FF

133 at our institution since 1985, 75 developed distant metastasis during a median follow-up of 49 month

134 e amounts of neuroepithelium and generated a distant metastasis entirely composed of rhabdomyoblasts.

135 en nadir + 2-ng/mL definition), freedom from distant metastasis (FFDM), cancer-specific survival (CSS

136 umulative incidences of local recurrence and distant metastasis for radical versus conservative group

137 re effective systemic therapy to improve the distant metastasis free rates.

138 survival, including poorer overall survival, distant metastasis free survival, relapse free survival,

139 n species, and that these networks predicted distant metastasis free survival.

140 f a basal-like or TNBC phenotype and reduced distant metastasis free survival.

141 The 5-year distant-metastasis free survival was 94.9% for low-risk

142 s with high LOX-expressing tumours have poor distant metastasis-free and overall survivals.

143 val was 83.7% (95% CI 72.6-94.9), the 2 year distant metastasis-free interval was 90.8% (82.2-99.5),

144 The association between GRPR expression and distant metastasis-free interval was also examined.

145 ars, the triple negative cohort had a poorer distant metastasis-free rate compared with the other sub

146 Ten-year distant metastasis-free rate was 82%.

147 free (PF), regional PF, locoregional PF, and distant metastasis-free rates were 92.6%, 90.8%, 89.3%,

148 l (OS), progression-free survival (PFS), and distant metastasis-free survival (DMFS) (Hazard Ratios [

149 Secondary end points were distant metastasis-free survival (DMFS) and overall surv

150 There was also an improvement in distant metastasis-free survival (DMFS) for SNB patients

151 survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and local-regio

152 ence-free survival (RFS; primary end point), distant metastasis-free survival (DMFS), and overall sur

153 datasets, where the objective is predicting distant metastasis-free survival (DMFS).

154 er was associated with significantly reduced distant metastasis-free survival (DMFS; P=0.01) and dise

155 odel revealed no significant differences for distant metastasis-free survival (hazard ratio [HR], 1.2

156 -regional control (HR, 0.04; P = 0.002), and distant metastasis-free survival (HR, 0.07; P = 0.028).

157 DeltaSUV1-3 was an independent predictor of distant metastasis-free survival (P = 0.01).

158 ff for DeltaSUV1-3 was the best predictor of distant metastasis-free survival (P = 0.05).

159 emical recurrence-free survival [bRFS], 29%; distant metastasis-free survival [DMFS], 53%; prostate c

160 was new ipsilateral breast cancer events and distant metastasis-free survival analyzed according to i

161 Rates of distant metastasis-free survival and freedom from relaps

162 dule requires additional assessment based on distant metastasis-free survival and overall survival en

163 Findings were similar for distant metastasis-free survival and overall survival.

164 ents, we show that both overall survival and distant metastasis-free survival are markedly diminished

165 The rate of distant metastasis-free survival at 5 years was 48.3% in

166 tive patients showed significantly shortened distant metastasis-free survival for patients with high

167 HER2+ subtypes had median distant metastasis-free survival of 99 months [95% confi

168 urrence-free survival, overall survival, and distant metastasis-free survival than placebo.

169 rval [CI] 1.28-4.97, P < 0.01) and a shorter distant metastasis-free survival time (HR = 3.61, 95% CI

170 Distant metastasis-free survival was the primary end poi

171 rogression-free survival, local failure, and distant metastasis-free survival were not different betw

172 and biologic factors, disease-free survival, distant metastasis-free survival, and overall survival (

173 ondary end points included overall survival, distant metastasis-free survival, and safety.

174 ondary end points included overall survival, distant metastasis-free survival, freedom from relapse,

175 ed overall survival, local and regional PFS, distant metastasis-free survival, quality of life, adver

176 statistically significantly associated with distant metastasis-free survival.

177 s no statistically significant difference in distant metastasis-free survival.

178 w Foxa1 expressions are associated with poor distant metastasis-free survival.

179 and is associated with decreased overall and distant metastasis-free survival.

180 ll, local recurrence-free, disease-free, and distant metastasis-free survivals (P = 0.033, 0.014, <0.

181 = 0.006), lymphatic-spread-free (P = 0.041), distant-metastasis-free (P = 0.029), and melanoma-specif

182 f SDPR correlates with significantly reduced distant-metastasis-free and relapse-free survival of bre

183 no significant difference between groups for distant-metastasis-free interval (HR 0.88, 95% CI 0.73-1

184 In the Erasmus Breast Cancer Cohort, 5-year distant-metastasis-free survival was longer in patients

185 s tumor growth, local metastasis burden, and distant metastasis frequency in this model of NEPC.

186 r patients with extensive local invasion and distant metastasis frequently do not respond to standard

187 Patients with locally advanced cancer or distant metastasis frequently receive prolonged treatmen

188 AST were independent predictors of recurrent distant metastasis from primary stage II or III colorect

189 ients were positive in the pelvis (group A), distant metastasis (group B) were detected in 72 of 605

190 95% CI 1.10-2.10), while patients with more distant metastasis had a 27% statistically non-significa

191 Patients with distant metastasis had no increase in disease-specific m

192 tive subtype was an independent predictor of distant metastasis (hazard ratio = 2.14; 95% CI, 1.31 to

193 us covariate was an independent predictor of distant metastasis (hazard ratio [HR] 1.181 [95% CI 1.07

194 groups with low and high risk for developing distant metastasis (hazard ratio, 4.8; P = .0498, log-ra

195 igh in both TCRS and PRS had a lower risk of distant metastasis (HR, 0.69; 95% CI, 0.49 to 0.98).

196 (HR: 12.8, 95% CI: 3 to 49) and incidence of distant metastasis (HR: 8.7, 95% CI: 2 to 31) correlated

197 PET/CT was positive for pelvic LN or distant metastasis in 36 of 107 patients (33.6%).

198 eduction/eradication of the primary tumor or distant metastasis in a CD8(+) T cell-dependent fashion.

199 01 (everolimus) results in the occurrence of distant metastasis in a rat model of pancreatic cancer.

200 e long ectopic blood vessels and (c) enhance distant metastasis in a zebrafish xenograft model.

201 owever, two studies showed a reduced risk of distant metastasis in advanced nodal stage patients.

202 rates high specificity and PPV for detecting distant metastasis in cervical and endometrial cancer an

203 cell lines and was associated with nodal and distant metastasis in CRC patient samples.

204 The lungs are the most frequent sites of distant metastasis in differentiated thyroid carcinoma.

205 pression is associated with a higher risk of distant metastasis in ER+ breast cancer patients.

206 dered the main cause of local recurrence and distant metastasis in lung cancer.

207 on tomography is used to assess regional and distant metastasis in many malignancies.

208 nd AURKA inhibitors impairs tumor growth and distant metastasis in mice harboring xenografts of breas

209 sential for Twist1-induced cell invasion and distant metastasis in mice.

210 KPNA4 significantly reduces PCa invasion and distant metastasis in mouse models.

211 Antioxidants promoted distant metastasis in NSG mice.

212 tage, higher tumor grade and the presence of distant metastasis in PanNET patients.

213 CG protein expression in primary tumors with distant metastasis in patients regardless of the cancer

214 We established the frequency of distant metastasis in patients who developed cancer duri

215 The noninferior accuracy for diagnosis of distant metastasis in patients with common pediatric tum

216 correlated with the extent of lymph node and distant metastasis in patients with CRC and served as a

217 ron emission tomography (PET) for predicting distant metastasis in patients with early-stage non-smal

218 (PET)/computed tomography (CT) in detecting distant metastasis in patients with local-regionally adv

219 up of patients with increased probability of distant metastasis in the independent validation set of

220 PET and applied it to track spontaneous and distant metastasis in the presence or absence of genotox

221 At 5 years, the rate of survival without distant metastasis in this group was 94.7% (95% confiden

222 association of one 3q driver gene FXR1 with distant metastasis in TNBC (P = 0.01) was further valida

223 an breast cancer cells specifically inhibits distant metastasis in vivo and invasive behavior in vitr

224 resulted in a higher incidence of local and distant metastasis in vivo.

225 CF, and relapse (locoregional failure [LRF], distant metastasis) in this patient group.

226 Distant metastasis is frequently observed in patients wi

227 outcome in ICC and should be pursued unless distant metastasis is present.

228 Distant metastasis is the main cause of death from renal

229 a (HNSCC) is that local invasion rather than distant metastasis is the major route for dissemination.

230 AF mutations, local recurrence, regional and distant metastasis, melanoma-related mortality, and all-

231 patients (3.4%) because of the occurrence of distant metastasis (n = 5) or other reasons.

232 ymph node involvement, and evidence of overt distant metastasis obtained by imaging technologies.

233 No disease progression, relapse, or distant metastasis occurred during follow-up.

234 In dogs and children distant metastasis occurs in >80% of individuals treated

235 l lymphangiogenesis, lymphatic invasion, and distant metastasis of breast cancer cells.

236 re is no effective therapy for patients with distant metastasis of medullary thyroid carcinoma (MTC).

237 oPrint is able to predict the development of distant metastasis of patients with stage II colon cance

238 The C-index for 10-year distant metastasis of the clinical model alone was 0.76;

239 m in greatest dimension were associated with distant metastasis or death.

240 tudy, none of the patients with TC developed distant metastasis or died from the disease without an i

241 ted a significantly higher detection rate of distant metastasis or synchronous cancer than strategies

242 The true detection rate of distant metastasis or synchronous cancer with PET/CT was

243 ed with a reduced proportion of cancers with distant metastasis (OR 0.69, 95% CI 0.57-0.83, p(sig)<0.

244 utcomes (local recurrence, nodal metastasis, distant metastasis, or death from skin cancer).

245 irst and RT-first arms in time to any event, distant metastasis, or death.

246 outcome (local recurrence, nodal metastasis, distant metastasis, or disease-specific death) of CSCCs

247 ognostic factors for cumulative incidence of distant metastasis (P < .001 and P = .035, respectively)

248 els compared to tumors from patients without distant metastasis (P < 0.001).

249 RT (P = .0008) and reduced the frequency of distant metastasis (P = .0069) compared with STAD plus R

250 reduced tumor volume (P = 0.012), local and distant metastasis (P = 0.002), and angiogenesis (P = 0.

251 T stage (P < 0.001), N stage (P = 0.023) and distant metastasis (P = 0.033).

252 lated with depth of invasion (P = 0.003) and distant metastasis (P = 0.0331), but only marginally wit

253 (P = 0.0259), the nodal status (P < 0.0001), distant metastasis (P = 0.0354), the stage (P < 0.0001),

254 0.0381), lymph node metastasis (P = 0.0323), distant metastasis (P = 0.045), higher TNM stage (I and

255 tage (P<0.001), poor prognosis (P<0.001) and distant metastasis (P=0.008).

256 TNBC) has high rates of local recurrence and distant metastasis, partially due to its high invasivene

257 In addition, tumors from patients with known distant metastasis presented reduced NPM1 protein levels

258 group stratification, histology, presence of distant metastasis, radioactive iodine trapping ability,

259 was to test this hypothesis by comparing the distant metastasis rate (DMR) on initial (18)F-FDG PET/C

260 After 15 years of follow-up, distant metastasis rate, overall survival, and breast ca

261 for patients in the training cohort, 10-year distant metastasis rates for National Comprehensive Canc

262 ier clinical-genomic risk groups had 10-year distant metastasis rates of 3.5%, 29.4%, and 54.6%, for

263 The 5-year local-regional recurrence and distant metastasis rates were 25% (95% CI, 20%-30%) and

264 he estimated 2-year locoregional relapse and distant metastasis rates were 34.7% and 16.1%, respectiv

265 is demonstrated by its ability to enrich for distant metastasis related genes derived from noisy expr

266 have a poor prognosis and high incidence of distant metastasis, relative to other breast cancer subt

267 include 97 tumors showing lymph node and/or distant metastasis reveals a significant correlation bet

268 he results were correlated with metachronous distant metastasis risk (n = 22 patients).

269 h increased risk for local recurrence and/or distant metastasis (risk ratio, 1.35; 95% CI, 1.09 to 1.

270 , 1.03 to 1.45) and lethal disease (death or distant metastasis; RR, 1.19; 95% CI, 1.00 to 1.43).

271 at spontaneously develops thyroid cancer and distant metastasis similar to human follicular thyroid c

272 signatures and clinical outcomes, including distant metastasis, survival, and tumor grade.

273 ho had radiotherapy had a lower incidence of distant metastasis than did patients who did not have ra

274 nd subgroup differences were less marked for distant metastasis than for regional relapse.

275 PET imaging characteristics associated with distant metastasis that could potentially help practitio

276 ure led to a 5-year rate of survival without distant metastasis that was 1.5 percentage points lower

277 Breast cancer cells facilitate distant metastasis through the induction of immunosuppre

278 to patients revealing no more than 1 type of distant metastasis to avoid confounding by other distant

279 ate-rich diet enhanced lung colonization and distant metastasis to lymph nodes and decreased overall

280 ry tumors and the microenvironment of future distant metastasis via tumor-derived factors.

281 Overall prevalence of distant metastasis was 13.7% (21 of 153) for cervical ca

282 Distant metastasis was highest in patients with RET/PTC-

283 No definitive association with distant metastasis was seen in multivariable Cox proport

284 tes of local tumor relapse, enucleation, and distant metastasis were 3.9%, 3.7%, and 13.4%, respectiv

285 ode metastasis, extrathyroidal invasion, and distant metastasis were also included in the model, the

286 The effects of stress on distant metastasis were also inhibited by in vivo macrop

287 of local treatment failure and occurrence of distant metastasis were determined.

288 Locoregional recurrence and distant metastasis were included as intermediate states,

289 Similar rates of survival without distant metastasis were reported in the subgroup of pati

290 ve increased incidence of mammary tumors and distant metastasis when compared with mice that had full

291 Standard imaging modalities often detect distant metastasis when the burden of disease is high, u

292 liation because of locally advanced stage or distant metastasis, where it cannot be subjected to cura

293 c-Myc mice developed spontaneous HCC without distant metastasis, whereas Alb/AEG-1/c-Myc mice develop

294 ham histological grade, Ki67 expression, and distant metastasis, whereas high PIP4K2B expression stro

295 Distant metastasis, which results in >90% of cancer-rela

296 also promoted hematogenous dissemination and distant metastasis, which was linked to neuroblastoma ce

297 f local progression (P = .02), as opposed to distant metastasis, which was the case in the high-p16 c

298 cant parameter to predict the development of distant metastasis with a hazard ratio of 4.28 (95% conf

299 1L2 knockdown, or MTHFD1 knockdown inhibited distant metastasis without significantly affecting the g

300 rval for the rate of 5-year survival without distant metastasis would be 92% (i.e., the noninferiorit